Figures & data
Table 1. Up-front glioblastoma trials.
Table 2. Recurrent glioblastoma trials.
Gilbert MR, Wang M, Aldape KD et al. RTOG 0525: a randomized Phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2006). Bach F, Westphal M; OSAG-101 Study Group. Current status of a Phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 154s (2011) (Abstract 2059). Chinot OL, Wick W, Saran F et al. AVAglio: a Phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 16s (2011) (Abstract TPS136). Verschaeve V, D’Hondt LA, Verbeke LM et al. CeCil: a randomized, noncomparative Phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 15s (2011) (Abstract TPS134). Chauffert B, Feuvret L, Bonnetain F et al. Randomized multicenter Phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: interim results of the TEMAVIR study from ANOCEF group. J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2029). Hofland KF, Hansen S, Sorensen M et al. Randomized Phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoreaadiotherapy in newly diagnosed primary glioblastoma multiforme. J. Clin. Oncol.29(15 Suppl., part I of II), 153s (2011) (Abstract 2052). Wick W, Steinbach J, Combs SE et al. Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: a multicenter, open-label, uncontrolled Phase II study. J. Clin. Oncol.29(15 Suppl., part I of II), 141s (2011) (Abstract 2007). Khasraw M, McCowatt S, Kerestes Z, Buyse ME, Back M, Wheeler H. Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB, and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). J. Clin. Oncol.29(15 Suppl., part I of II), 15s (2011) (Abstract TPS133). Omuro AMP, Beal K, Karimi S et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2028). Lou E, Reardon DA, Peters K et al. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 153s (2011) (Abstract 2055). Quant EC, Batchelor T, Lassman AB et al. Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 157s (2011) (Abstract 2069). Beauchesnes PD, Faure G, Noel G et al. Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFRAC a Phase II trial. J. Clin. Oncol.29(15 Suppl., part I of II), 158s (2011) (Abstract 2073). Vredenburgh JJ, Desjardins A, Reardon DA et al. Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). J. Clin. Oncol.29(15 Suppl., part I of II), 164s (2011) (Abstract 2098). Jeyapalan SA, Goldmann M, Donahur J et al. A Phase II study of paclitaxel poliglumex (PPX), temozolomide (TMX), and radiation (RT) for newly diagnosed high-grade gliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 149s (2011) (Abstract 2036). Phuphanich S, Wheeler CJ, Rudnick J et al. Glioma-associated antigens associated with prolonged survival in a Phase I study of ICT-107 for patients with newly diagnosed glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 150s (2011) (Abstract 2042). DeGroot JF, Cloughesy T, Lieberman FS et al. Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. J. Clin. Oncol.29(15 Suppl., part I of II), 150s (2011) (Abstract 2043). Wen PY, Puduvalli VK, Kuhn JG et al. Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. J. Clin. Oncol.29(15 Suppl., part I of II), 148s (2011) (Abstract 2032). Eisenstat DD, Nabors LB, Mason WP et al. A Phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 142s (2011) (Abstract 2010). Soffietti R, Trevisan E, Ruda R et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J. Clin. Oncol.29(15 Suppl., part I of II), 146s (2011) (Abstract 2027). Reardon DA, Vredenburgh JJ, Desjardins A et al. Bevacizumab (BV) continuation following BV progression: meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J. Clin. Oncol.29(15 Suppl., part I of II), 147s (2011) (Abstract 2030). Jaeckle KA, Schiff D, Anderson SK et al. NCCTG N0572 Phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: a North Central Cancer Treatment Group study. J. Clin. Oncol.29(15 Suppl., part I of II), 148s (2011) (Abstract 2033). Hammond S, Norden AD, Lesser GJ et al. Phase II study of dose-intense temozolomide in recurrent glioblastoma: Phase II study of dose-intense temozolomide in recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 149s (2011) (Abstract 2038). Bota DA, Erogluz, Reardon DA et al. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J. Clin. Oncol.29(15 Suppl., part I of II), 154s (2011) (Abstract 2056). Paccepelo ALolli I, Scocciantis et al. Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: a pooled analysis. J. Clin. Oncol.29(15 Suppl., part I of II), 155s (2011) (Abstract 2060). Zustovich F, Landi L, Lombaardi G et al. Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: a Phase II study. J. Clin. Oncol.29(15 Suppl., part I of II), 160s (2011) (Abstract 2080). Cuneo KC, Cabrera AR, Sampson JH et al. Safety results from prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J. Clin. Oncol.29(15 Suppl., part I of II), 160s (2011) (Abstract 2082). Kim LJ, Chamberlain MC, Zhu J et al. Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab. J. Clin. Oncol.29(15 Suppl., part I of II), 162s (2011) (Abstract 2088). Drappatz J, Raizer JJ, Schiff D et al. A Phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). J. Clin. Oncol.29(15 Suppl., part I of II), 152s (2011) (Abstract 2050). Raizer JJ, Rice L, Rademaker A et al. A Phase I trial of laromustine (VPN40101M) and temozolomide for patients with malignant gliomas in first relapse of progression. J. Clin. Oncol.29(15 Suppl., part I of II), 156s (2011) (Abstract 2064).